EGFR and non-small cell lung carcinoma: The primary oncogenic driver in NSCLC is Epidermal Growth Factor Receptor (EGFR) mutation, whose classic mutations, such as exon 19 deletion and exon 21 mutation, are key targets for NSCLC therapy.